Omnicell (OMCL) Stock Price

Omnicell Price

NASDAQ·CLOSED
37.32USD+0.51 (+1.37 %)
Market closed

Revenue has compounded at 11.3% per year over the past 19 years to 1.18 B USD. Earnings per share have declined at 10.3% per year over the last 19 years. Omnicell's net margin stands at 0.2%, down from 6.9% several years earlier. Analysts set a median price target of 55.08 USD, implying 47.6% above the current price. Of 14 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 27% above its 52-week low.

Omnicell stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Omnicell over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Omnicell stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Omnicell's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Omnicell Stock Price History
DateOmnicell Price
8/10/202637.32 USD
8/7/202636.81 USD
8/6/202636.16 USD
8/5/202637.29 USD
8/4/202636.77 USD
8/3/202637.65 USD
7/31/202635.37 USD
7/30/202637.11 USD
7/29/202642.45 USD
7/27/202641.00 USD
7/23/202639.86 USD
7/22/202640.86 USD
7/21/202641.83 USD
7/20/202645.22 USD
7/17/202645.87 USD
7/16/202647.00 USD
7/15/202646.82 USD
7/14/202645.94 USD
7/13/202646.66 USD
7/10/202644.92 USD
7/9/202645.59 USD
7/8/202643.74 USD
7/7/202644.36 USD
7/6/202643.41 USD
7/2/202643.03 USD
7/1/202641.93 USD
6/30/202641.52 USD
6/29/202641.05 USD
6/26/202640.13 USD
6/25/202639.53 USD
6/24/202639.49 USD
6/23/202638.41 USD
6/22/202639.24 USD
6/18/202637.87 USD
6/17/202639.67 USD
6/16/202640.29 USD
6/15/202639.22 USD
6/12/202637.99 USD
6/11/202637.33 USD
6/10/202639.44 USD
6/9/202640.69 USD
6/8/202641.95 USD
6/5/202643.42 USD
6/4/202643.27 USD
6/3/202641.26 USD
6/2/202642.40 USD
6/1/202644.15 USD
5/29/202644.39 USD
5/28/202643.46 USD
5/27/202642.62 USD
5/26/202644.26 USD
5/22/202643.95 USD
5/21/202644.00 USD
5/20/202644.51 USD
5/19/202643.82 USD
5/18/202643.22 USD
5/15/202643.12 USD
5/14/202643.80 USD
5/13/202643.17 USD
5/12/202643.70 USD
5/8/202643.82 USD
5/7/202643.33 USD
5/5/202643.56 USD
5/4/202643.44 USD
5/1/202642.80 USD
4/30/202641.42 USD
4/29/202643.10 USD
4/28/202645.51 USD
4/27/202637.63 USD
4/24/202637.37 USD
4/23/202636.37 USD
4/22/202636.65 USD
4/21/202636.75 USD
4/20/202637.80 USD
4/17/202638.28 USD
4/16/202637.60 USD
4/15/202637.53 USD
4/14/202636.33 USD
4/13/202635.01 USD
4/10/202634.40 USD
4/9/202635.47 USD
4/8/202635.57 USD
4/7/202634.50 USD
4/6/202634.11 USD
4/2/202634.15 USD
4/1/202634.15 USD
3/31/202633.94 USD
3/30/202633.38 USD
3/29/202632.35 USD
3/27/202632.75 USD
3/26/202632.75 USD
3/25/202635.20 USD
3/24/202634.94 USD
3/23/202634.46 USD
3/22/202634.31 USD
3/20/202633.09 USD
3/19/202633.09 USD
3/18/202633.40 USD
3/17/202634.03 USD
3/16/202635.09 USD
3/15/202634.29 USD
3/13/202634.40 USD
3/12/202634.40 USD
3/11/202635.10 USD
3/10/202637.48 USD
3/9/202638.99 USD
3/8/202639.83 USD
3/6/202641.30 USD
3/5/202641.30 USD
3/4/202642.25 USD
3/3/202641.53 USD
3/2/202640.80 USD
3/1/202641.25 USD
2/27/202641.10 USD
2/26/202641.10 USD
2/25/202641.93 USD
2/24/202641.37 USD
2/23/202640.15 USD
2/22/202639.56 USD
2/20/202640.26 USD
2/19/202640.26 USD
2/18/202638.63 USD
2/17/202638.61 USD
2/16/202637.37 USD
2/13/202636.50 USD
2/12/202636.50 USD
2/11/202636.18 USD
2/10/202637.82 USD
2/9/202639.00 USD
2/8/202636.50 USD
2/6/202637.07 USD
2/5/202637.07 USD
2/4/202639.08 USD
2/3/202646.69 USD
2/2/202646.04 USD
2/1/202648.70 USD
1/30/202648.50 USD
1/29/202648.50 USD
1/28/202649.09 USD
1/27/202649.04 USD
1/26/202649.96 USD
1/25/202650.32 USD
1/23/202650.30 USD
1/22/202650.30 USD
1/21/202651.32 USD
1/20/202650.48 USD
1/19/202649.06 USD
1/16/202650.52 USD
1/15/202650.52 USD
1/14/202650.98 USD
1/13/202650.72 USD
1/12/202651.39 USD
1/11/202651.19 USD
1/9/202650.74 USD
1/8/202650.74 USD
1/7/202650.59 USD
1/6/202647.45 USD
1/5/202647.07 USD
1/4/202646.93 USD
1/2/202645.14 USD
1/1/202645.14 USD
12/31/202545.30 USD
12/30/202545.30 USD
12/29/202545.92 USD
12/28/202546.14 USD
12/26/202546.40 USD
12/25/202546.40 USD
12/24/202545.78 USD
12/23/202545.78 USD
12/22/202545.57 USD
12/21/202545.70 USD
12/19/202546.84 USD
12/18/202546.84 USD
12/17/202546.25 USD
12/16/202545.79 USD
12/15/202544.74 USD
12/14/202543.27 USD
12/12/202543.86 USD
12/11/202543.86 USD
12/10/202543.29 USD
12/9/202543.97 USD
12/8/202543.49 USD
12/7/202543.55 USD
12/5/202540.50 USD
12/4/202540.50 USD
12/3/202539.61 USD
12/2/202540.48 USD
12/1/202538.46 USD
11/30/202536.12 USD
11/28/202536.51 USD
11/27/202536.51 USD
11/26/202536.66 USD
11/25/202536.66 USD
11/24/202537.00 USD
11/23/202536.24 USD
11/21/202536.00 USD
11/20/202536.00 USD
11/19/202534.32 USD
11/18/202534.53 USD
11/17/202534.42 USD
11/16/202534.19 USD
11/14/202535.12 USD
11/13/202535.12 USD
11/12/202535.56 USD
11/11/202536.86 USD
11/10/202537.11 USD
11/9/202536.81 USD
11/7/202535.68 USD
11/6/202535.68 USD
11/5/202535.76 USD
11/4/202535.74 USD
11/3/202534.50 USD
11/2/202533.37 USD
10/31/202533.57 USD
10/30/202533.57 USD
10/29/202533.58 USD
10/28/202529.57 USD
10/27/202529.94 USD
10/26/202530.54 USD
10/23/202531.10 USD
10/22/202530.89 USD
10/21/202530.45 USD
10/20/202530.98 USD
10/19/202530.20 USD
10/16/202529.90 USD
10/15/202530.30 USD
10/14/202529.92 USD
10/13/202529.69 USD
10/12/202529.46 USD
10/9/202529.72 USD
10/8/202531.12 USD
10/7/202531.45 USD
10/6/202530.25 USD
10/5/202530.52 USD
10/2/202530.95 USD
10/1/202529.98 USD
9/30/202529.96 USD
9/29/202530.45 USD
9/28/202530.34 USD
9/25/202530.72 USD
9/24/202530.50 USD
9/23/202530.88 USD
9/22/202531.00 USD
9/21/202531.62 USD
9/18/202531.34 USD
9/17/202531.80 USD
9/16/202531.18 USD
9/15/202532.32 USD
9/14/202532.26 USD
9/11/202531.83 USD
9/10/202533.28 USD
9/9/202531.86 USD
9/8/202532.77 USD
9/7/202532.33 USD
9/4/202532.11 USD
9/3/202533.12 USD
9/2/202532.82 USD
9/1/202532.10 USD
8/28/202532.59 USD
8/27/202533.28 USD
8/26/202533.23 USD
8/25/202532.72 USD
8/24/202533.09 USD
8/21/202533.62 USD
8/20/202531.89 USD
8/19/202531.75 USD
8/18/202531.91 USD
8/17/202531.61 USD
8/14/202531.69 USD
8/13/202531.47 USD
8/12/202531.34 USD
Access this data via the Eulerpool API
Get Free API Key

Omnicell Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
1.13 B USD
89.51 M USD
77.85 M USD
Jan 1, 2022
1.30 B USD
-2.32 M USD
5.65 M USD
Jan 1, 2023
1.15 B USD
-34.87 M USD
-20.37 M USD
Jan 1, 2024
1.11 B USD
337,000.00 USD
12.53 M USD
Jan 1, 2025
1.18 B USD
11.67 M USD
2.05 M USD
Jan 1, 2026 (e)
1.25 B USD
25.60 M USD
88.04 M USD
Jan 1, 2027 (e)
1.32 B USD
27.00 M USD
99.74 M USD
Jan 1, 2028 (e)
1.42 B USD
29.13 M USD
104.51 M USD

Omnicell Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 11:32 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
0.380.440.480.690.720.790.900.891.131.301.151.111.181.251.321.42
21.0215.7910.0042.983.479.9213.98-0.5626.9114.40-11.43-3.056.475.325.457.91
53.4252.9551.0345.2344.9747.2748.6146.3048.9445.4143.2442.3642.9142.9142.9142.91
203.00233.00247.00313.00322.00372.00436.00413.00554.00588.00496.00471.00508.00535.03564.21608.83
35.0049.0048.006.005.0044.0078.0035.0089.00-2.00-34.00–11.0025.0027.0029.00
9.2111.149.920.870.705.598.703.927.86-0.15-2.96–0.932.002.052.04
23.0030.0030.00–20.0037.0061.0032.0077.005.00-20.0012.002.0088.0099.00104.00
43.7530.43–––85.0064.86-47.54140.63-93.51-500.00-160.00-83.334,300.0012.505.05
36.6136.5936.1737.2639.4841.4743.3344.0049.8544.6845.5046.2644.9644.9644.9644.96
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Omnicell generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Omnicell retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Omnicell's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Omnicell has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Omnicell's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Omnicell stock margins

The Omnicell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Omnicell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Omnicell.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
49.00 %
7.91 %
6.88 %
Jan 1, 2022
45.45 %
-0.18 %
0.44 %
Jan 1, 2023
43.31 %
-3.04 %
-1.78 %
Jan 1, 2024
42.35 %
0.03 %
1.13 %
Jan 1, 2025
42.88 %
0.98 %
0.17 %
Jan 1, 2026 (e)
42.88 %
2.05 %
7.06 %
Jan 1, 2027 (e)
42.88 %
2.05 %
7.58 %
Jan 1, 2028 (e)
42.88 %
2.05 %
7.36 %

Omnicell Stock Revenue, EBIT, Earnings per Share

The Omnicell earnings per share therefore indicates how much revenue Omnicell has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
22.71 USD
1.80 USD
1.56 USD
Jan 1, 2022
29.01 USD
-0.05 USD
0.13 USD
Jan 1, 2023
25.21 USD
-0.77 USD
-0.45 USD
Jan 1, 2024
24.05 USD
0.01 USD
0.27 USD
Jan 1, 2025
26.35 USD
0.26 USD
0.05 USD
Jan 1, 2026 (e)
27.45 USD
0.57 USD
1.94 USD
Jan 1, 2027 (e)
28.95 USD
0.60 USD
2.20 USD
Jan 1, 2028 (e)
31.23 USD
0.65 USD
2.30 USD

Omnicell business model & stock analysis

Omnicell Inc. is a leading company in the healthcare industry, specializing in the development and provision of innovative automation solutions for medication and other critical medical supplies. The company was founded in 1992 and is headquartered in Mountain View, California, USA. Over the years, Omnicell has grown into a global company with offices in North America, Europe, Asia, and the Middle East. Omnicell's business model is to offer products, services, and solutions that allow healthcare facilities to optimize their processes, increase patient safety, and save costs. Omnicell provides innovative automation solutions, particularly for medication management, sterilization, and inventory control. Omnicell offers various solutions to improve medication management in clinics. This includes, for example, the medication cabinet, which has an integrated computer system that allows for the quick and easy identification and retrieval of needed medications. Omnicell also offers solutions for sterilizing medical materials to ensure patient safety, as well as automated storage systems for managing medical supplies. In recent years, the company has focused heavily on developing solutions to improve patient safety. One example is Omnicell's Medical Intelligence platform, which automatically detects and notifies of medication errors and other issues, thereby enhancing patient safety. Omnicell's products are used by a wide range of healthcare facilities, from small doctor's offices to large hospitals and health centers. The company has also established relationships with major retailers to sell its products, such as CVS and Walgreens in the USA. In addition to its core products and services, Omnicell also provides training and support to customers to ensure they can make optimal use of their products. The company also has its own research and development department to continuously develop new and innovative products and solutions. Overall, Omnicell aims to transform the healthcare industry through innovative automation solutions. Through its products, services, and solutions, the company has already helped many healthcare facilities improve their processes and increase patient safety. Omnicell will continue to invest in the development of new products and technologies to optimize the healthcare industry in the long term.

Omnicell SWOT Analysis

Strengths

Omnicell Inc possesses several strengths that contribute to its success in the market:

  • Strong technological capabilities and innovative solutions
  • Established reputation and trusted brand in the healthcare industry
  • Extensive product portfolio catering to diverse customer needs
  • Global presence and a wide customer base
  • Strong financial position and steady revenue growth

Weaknesses

Despite its strengths, Omnicell Inc also faces certain weaknesses that can hinder its growth:

  • Dependency on a limited number of key customers
  • Reliance on external suppliers for critical components
  • High costs of research and development
  • Potential vulnerability to regulatory changes in the healthcare industry
  • Limited market share in certain geographic regions

Opportunities

Omnicell Inc can leverage the following opportunities to further expand its business:

  • Increasing demand for automated medication management systems
  • Growing adoption of cloud-based healthcare solutions
  • Expansion into emerging markets with untapped potential
  • Strategic partnerships and acquisitions to enhance product offerings
  • Advancements in artificial intelligence and machine learning technologies

Threats

Omnicell Inc faces the following threats that could negatively impact its performance:

  • Intense competition from established players and new entrants
  • Potential cybersecurity risks and data breaches
  • Volatility in healthcare policies and reimbursement systems
  • Economic downturns affecting healthcare spending
  • Rapid technological advancements leading to product obsolescence

Omnicell Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Omnicell Employees
Details
Date
Omnicell Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Omnicell Segments

Omnicell Revenue by Segment (1/4)

  • Max

Product revenues
Service revenues
Services and other revenues
Details
Date
Product revenues
Service revenues
Services and other revenues
Jan 1, 2024
630.51 M USD
0.00 USD
481.73 M USD
Jan 1, 2025
665.70 M USD
519.15 M USD
0.00 USD

Omnicell Revenue by Segment (2/4)

  • Max

Connected devices, software licenses, and other
Technical services
SaaS and Expert Services
Consumables
Details
Date
Connected devices, software licenses, and other
Technical services
SaaS and Expert Services
Advanced Services
SaaS, subscription software, and technology-enabled services
Consumables
Jan 1, 2024
539.17 M USD
238.21 M USD
243.52 M USD
0.00 USD
0.00 USD
91.34 M USD
Jan 1, 2025
565.48 M USD
260.06 M USD
259.09 M USD
0.00 USD
0.00 USD
100.22 M USD

Omnicell Revenue by Segment (3/4)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Product revenues
Product
Service
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

Omnicell Revenue by Segment (4/4)

  • Max

Reportable Segment
Details
Date
Reportable Segment
Jan 1, 2024
1.11 B USD
Jan 1, 2025
1.18 B USD

Omnicell Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

United States
International
Other Countries
Foreign Countries
Details
Date
United States
International
Other Countries
Foreign Countries
Jan 1, 2017
617.27 M USD
0.00 USD
98.90 M USD
0.00 USD
Jan 1, 2019
806.90 M USD
90.13 M USD
0.00 USD
0.00 USD
Jan 1, 2020
797.60 M USD
94.61 M USD
0.00 USD
0.00 USD
Jan 1, 2021
1.02 B USD
111.23 M USD
0.00 USD
0.00 USD
Jan 1, 2022
1.17 B USD
127.75 M USD
0.00 USD
0.00 USD
Jan 1, 2023
1.01 B USD
135.73 M USD
0.00 USD
0.00 USD
Jan 1, 2024
1.01 B USD
99.87 M USD
0.00 USD
0.00 USD
Jan 1, 2025
1.07 B USD
119.77 M USD
0.00 USD
0.00 USD

Omnicell Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Omnicell historical P/E ratio, EBIT multiple, and P/S ratio

Omnicell annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Omnicell shares outstanding

The number of shares of Omnicell was 44.96 M in 2025. This indicates how many shares Omnicell is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
49.85 M Stocks
Jan 1, 2022
44.68 M Stocks
Jan 1, 2023
45.50 M Stocks
Jan 1, 2024
46.26 M Stocks
Jan 1, 2025
44.96 M Stocks
Jan 1, 2026 (e)
44.96 M Stocks
Jan 1, 2027 (e)
44.96 M Stocks
Jan 1, 2028 (e)
44.96 M Stocks

Current Omnicell forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.89 %
Buy
78.57 % (11)
Hold
21.43 % (3)
Sell
0.00 % (0)
12M Price Target
55.08
Last Price
37.32
Currency
USD
12M Return Potential
47.59 %
LTM Return
0 %

Omnicell Analyst Rating Actions

DateFirmActionRatingReliability
7/31/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
7/31/2026
Keybanc
Keybanc
MaintainedOverweight49
4/29/2026
Keybanc
Keybanc
MaintainedOverweight49
4/23/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
2/6/2026
Piper Sandler
Piper Sandler
MaintainedOverweight51
2/2/2026
Benchmark
Benchmark
MaintainedBuy71
1/8/2026
Keybanc
Keybanc
UpgradeSector WeightOverweight49
1/5/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
12/9/2025
B of A Securities
B of A Securities
MaintainedNeutral70
12/9/2025
Benchmark
Benchmark
MaintainedBuy71

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Omnicell Earnings Calls

2025

Omnicell Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/30/20260.48USD-316.46 MUSD-2026 Q2
2/5/20260.51USD-319.66 MUSD-2025 Q4
4/30/20240.32USD-267.92 MUSD-2024 Q1
2/26/20240.16USD-260.74 MUSD-2023 Q4
8/2/20230.39USD-308.52 MUSD-2023 Q2
4/26/20230.25USD-297.78 MUSD-2023 Q1
2/13/20230.09USD-292.05 MUSD-2022 Q4
11/2/20220.97USD-368.64 MUSD-2022 Q3
8/4/20220.87USD-344.54 MUSD-2022 Q2
4/28/20220.70USD-319.08 MUSD-2022 Q1
...

EESG©

Eulerpool ESG Scorecard© for the Omnicell stock

73/100
99
Environment
84
Social
36
Governance
E

Environment

20
Scope 1 - Direct Emissions335
Scope 2 - Indirect emissions from purchased energy4,910
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions5,245
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees40
Percentage of women in management—
Percentage of Asian employees15
Share of Asian management—
Percentage of Hispanic/Latino employees5
Hispano/Latino Management share—
Percentage of Black employees11
Black Management Share—
Percentage of white employees60
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Omnicell shareholder structure

% Name
15.86096%
BLACKROCK, INC.
BLACKROCK, INC.
7.07475%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
5.95741%
WELLINGTON MANAGEMENT GROUP LLP
WELLINGTON MANAGEMENT GROUP LLP
5.39257%
DIMENSIONAL FUND ADVISORS LP
DIMENSIONAL FUND ADVISORS LP
5.03647%
MILLENNIUM MANAGEMENT LLC
MILLENNIUM MANAGEMENT LLC
4.29256%
STATE STREET CORP
STATE STREET CORP
...

Omnicell Beneficial Ownership Filings (SEC 13D/G)

Free Float
96.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
15.90%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
15.30%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
10.79%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
9.60%
EIN #75-3019302
EIN #75-3019302
SEC ↗
7.13%
Vanguard Portfolio Management
Vanguard Portfolio Management
SEC ↗
6.80%
Coxe
Coxe
SEC ↗
6.74%
Massachusetts Financial Services Company ("MFS")
Massachusetts Financial Services Company ("MFS")
SEC ↗
6.70%
84-0964425
84-0964425
SEC ↗
6.56%
OAK RIDGE INVESTMENTS LLC36-4142388
OAK RIDGE INVESTMENTS LLC36-4142388
SEC ↗
6.00%
Wellington Management Group LLP
Wellington Management Group LLP
SEC ↗

Omnicell Executives and Management Board

14 members · avg. age 62 · 29 % women

RL

Mr. Randall Lipps (67)

Chairman of the Board, President, Chief Executive Officer · since 1992

8.17 M USD

Management

NE

Mr. Nchacha Etta (54)

Chief Financial Officer, Executive Vice President

3.14 M USD
NN

Mr. Nnamdi Njoku (48)

Chief Operating Officer, Executive Vice President

2.74 M USD
CM

Mr. Corey Manley (47)

Executive Vice President, Chief Legal and Administrative Officer

2.72 M USD
BR

Mr. Baird Radford (55)

Chief Financial Officer, Executive Vice President

–
KN

Ms. Kathleen Nemeth

Investor Relations · since 2024

–

Board of Directors

EV

Ms. Eileen Voynick (70)

Independent Director

350,249.00 USD
JB

Ms. Joanne Bauer (69)

Lead Independent Director

342,605.00 USD
MP

Mr. Mark Parrish (69)

Independent Director

311,023.00 USD
BS

Mr. Bruce Scott (69)

Independent Director

310,138.00 USD
RS

Mr. Robin Seim (65)

Independent Director · since 2006

297,273.00 USD
MG

Ms. Mary Garrett (66)

Independent Director

295,811.00 USD

Omnicell Supply Chain

Omnicell Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#Nameβ 1YTrend
1
Community Health Systems
Supplier·Health Care Providers & Services·US
-0.09
0.22
0.84
0.76
0.60
0.86
—
2
Premier A
Supplier·Health Care Providers & Services·US
0.24
0.05
-0.52
0.75
0.63
0.74
0.45
3
Ensign Group
Customer·Health Care Providers & Services·US
0.41
-0.17
0.78
-0.19
-0.24
0.73
-0.13
4
Walgreens Boots Alliance
Customer·Food & Staples Retailing·US
-0.20
0.22
0.66
0.45
0.31
0.70
0.07
5
CVS Health
Customer·Health Care Providers & Services·US
-0.28
0.34
0.32
-0.57
-0.50
0.62
-0.33
#Nameβ 1YTrend
1
BIO-key
Supplier·Software·US
-0.31
0.41
0.75
0.40
0.35
-0.58
—
2
Fresenius
Supplier·Customer·Health Care Providers & Services·DE
-0.62
0.26
-0.66
0.34
0.29
0.04
0.19
3
Twilio A
Supplier·Customer·IT Services·US
0.59
0.55
0.83
0.97
0.62
0.24
0.63

Frequently asked questions about Omnicell

Omnicell Inc is a leading healthcare technology company specializing in medication and supply management solutions. The company's business model revolves around providing automated systems and software solutions to hospitals, pharmacies, and other healthcare institutions. Omnicell aims to streamline workflow, improve patient safety, and optimize inventory management through its innovative technology and services. By offering a comprehensive suite of products, including medication dispensing cabinets, inventory management systems, and analytics software, Omnicell enhances operational efficiency and patient care quality. With its patient-centric approach, Omnicell Inc continues to be a trusted partner in the healthcare industry, delivering valuable solutions and improving overall healthcare outcomes.

Omnicell Inc is primarily active in the healthcare industry.

Omnicell Inc faces competition from various companies in the market. Some of its main competitors include McKesson Corporation, BD (Becton, Dickinson and Company), and Cantel Medical Corp. These companies operate in the healthcare solutions industry and provide similar products and services, which directly compete with Omnicell Inc. Additionally, companies like Capsa Healthcare and Baxter International Inc. also pose competition in certain segments. However, Omnicell Inc's strong market presence, innovative technologies, and comprehensive range of solutions help them remain competitive in the industry.

Omnicell Inc, a leading provider of medication management solutions, has a rich history and background. Established in 1992, Omnicell has continuously delivered innovative technologies to enhance patient safety and improve healthcare outcomes. The company's journey started with automated dispensing systems for medication storage and administration. Over the years, Omnicell expanded its product portfolio to include advanced solutions like robotic automation, analytics, and interoperability, catering to various healthcare settings globally. Today, Omnicell is renowned for its commitment to optimizing medication management processes, reducing errors, improving efficiency, and enabling healthcare professionals to focus on patient care. With a strong track record and dedication to innovation, Omnicell Inc has established itself as a trusted name in the healthcare industry.

Omnicell Inc has achieved several significant milestones since its inception. The company has become a global leader in automated healthcare solutions, catering to hospitals, pharmacies, and healthcare organizations. Omnicell's product portfolio includes advanced medication management systems, robotics, and software solutions improving patient safety and operational efficiency. The company has successfully expanded its global presence, established strategic partnerships, and received multiple industry accolades. Moreover, Omnicell has consistently focused on research and development, resulting in innovative technologies and improved patient outcomes. With its dedication to advancing healthcare through technology, Omnicell Inc continues to drive positive change in the industry.

Omnicell Inc is primarily present in the United States.

Omnicell Inc represents a strong commitment to improving patient care and safety through innovative medication management solutions. The company's corporate philosophy revolves around optimizing workflows and ensuring the right medication is delivered to the right patient at the right time. Omnicell is dedicated to enhancing operational efficiency, reducing medication errors, and promoting adherence to medication regimens. Their values include prioritizing patient-centricity, fostering a culture of collaboration, and driving continuous innovation in healthcare technology. Omnicell Inc strives to revolutionize medication management processes, ultimately helping healthcare organizations deliver better patient outcomes and improve overall healthcare efficiency.

Analysts currently set an average price target of 57.56 USD for the Omnicell stock (median: 55.08 USD), implying +54.2 % versus the latest price. The consensus is based on 14 analyst ratings.

Omnicell Analyst Price Targets 2026

14 analysts currently rate the Omnicell stock: 11 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Omnicell to generate revenue of 1.25 B USD and earnings per share of 1.96 USD.

Omnicell Analyst Price Targets 2026

Converted at the current exchange rate, the Omnicell share trades at 32.34 EUR (37.32 USD).

The Omnicell share (OMCL) is listed on 5 stock exchanges, including: NASDAQ (OMCL), Frankfurt (OC9.F), München (OC9.MU), Düsseldorf (OC9.DU), SIX (Zürich) (OC9.SW).

Omnicell Inc. is a US-based company that has gained worldwide recognition for its automation solutions for healthcare providers. The company positions itself as a reliable provider of innovative products and services in this field. The main products and services of Omnicell Inc. fall into four main areas: medication management, central pharmacy systems, workflow optimization, and analytics solutions. The medication management is the core of Omnicell Inc.'s business model. The company offers a variety of solutions for various areas including hospitals, pharmacies, and long-term care facilities to better automate medication inspection, preparation, dispensing, and returns. These solutions help nursing staff save time, minimize errors, and better meet patient needs. Central pharmacy systems are another important pillar of Omnicell Inc. These systems are designed to automate the workflow of pharmacies and distribution centers by monitoring and managing inventory and orders, optimizing product assignment to patients, and providing real-time data for inventory management. Workflow optimization is an important aspect of Omnicell Inc.'s business model. The company aims to increase the efficiency of nursing staff by automating workflows, reducing workload, and improving the quality of patient care. The company has developed a wide range of solutions for this purpose, including automated documentation, inventory management, and patient assignment. Analytics solutions also play an important role in Omnicell Inc.'s business strategy. The company offers innovative analysis tools that monitor prescription dispensing and collect data to optimize medication inventory and orders. These tools provide important business-relevant information that contributes to higher ROI in the healthcare industry. Overall, the company offers a wide range of products and services aimed at increasing efficiency, accuracy, and effectiveness in healthcare. Omnicell Inc. aims to meet the needs of providers and patients alike while ensuring the highest level of reliability, efficiency, and safety. With its innovative products, strong focus on customer service, and continuous investment in research and development, Omnicell Inc. has established itself as a market leader in automation solutions for healthcare providers.

The expected revenue of Omnicell is 1.25 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Omnicell is 88.04 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Omnicell is currently 19.06. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Omnicell stock.

The price-to-sales ratio (P/S) of Omnicell is currently 1.35. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Omnicell stock.

The Eulerpool Quality Score for Omnicell is 3/10.

The ISIN of Omnicell is US68213N1090. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Omnicell is 632313. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Omnicell is OMCL. The ticker symbol is used to trade Omnicell shares on the stock exchange.

Omnicell paid dividends every year for the past 0 years.

Omnicell is assigned to the 'Health' sector.

The dividends of Omnicell are distributed in USD.

All fundamentals and in-depth analysis of Omnicell

Our stock analysis for Omnicell stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Omnicell. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Omnicell Stock
Omnicell Revenue→
Omnicell Stock
Omnicell Net Income→
Omnicell Stock
Omnicell P/E→
Omnicell Stock
Omnicell P/S→
Omnicell Stock
Omnicell EBIT→
Omnicell Stock
Omnicell Dividend→
Omnicell Stock
Omnicell Directors Dealings→
Omnicell Stock
Omnicell Stocks→
Omnicell Stock
Omnicell Market capitalization→
Omnicell Stock
Omnicell Debt→
Omnicell Stock
Omnicell Liabilities→
Omnicell Stock
Omnicell Equity→
Omnicell Stock
Omnicell AAQS→
Omnicell Stock
Omnicell Employees→
Omnicell Stock
Omnicell ROE→
Omnicell Stock
Omnicell ROA→
Omnicell Stock
Omnicell ROCE→
Omnicell Stock
Omnicell News→
Omnicell Stock
Omnicell Analyst Price Targets→

Health Stocks

Omnimmune HoldingsOmniAbOncoclinicas do Brasil Servicos MedicosOmnia WellnessOncodesign Precision Medicine OpmOmerosOncoinvent AOmedOncologix TechOmda ASOncology InstituteOmada HealthAll Stocks A–Z →